⚠️ Research Use Only. This post is educational and does not constitute medical advice. All peptides discussed are sold for research purposes only. See our full disclaimer.
Immune modulation for research applications
Overview
The immune stack combines compounds targeting different layers of immune function — adaptive immunity modulation, innate antimicrobial activity, and inflammation suppression. It's particularly relevant for research into chronic infection, post-viral recovery, and dysregulated immune signaling.
Peptides in This Stack
Thymosin Alpha-1
Immune · High
Thymosin Alpha-1 is a 28-amino-acid peptide produced by the thymus, studied extensively for immune modulation and used clinically in over 35 countries.
LL-37
Immune · Moderate
LL-37 is a human antimicrobial peptide studied for its broad-spectrum antimicrobial, anti-biofilm, and immune-modulating properties.
KPV
Healing & Recovery · Low-Moderate
KPV is a tripeptide fragment of alpha-MSH studied for anti-inflammatory effects, particularly in gut and skin research.
Stack Rationale
Thymosin Alpha-1 modulates T-cell function and balances Th1/Th2 responses — the clinically established immune modulator. LL-37 provides direct antimicrobial activity against bacteria and biofilms, addressing infection itself. KPV reduces inflammation through NF-κB suppression. The combination addresses immune balance, microbial control, and inflammatory tone simultaneously.
Research Protocol
Sample protocol: Thymosin Alpha-1 1.6 mg subq twice weekly. LL-37 100-500 mcg subq several times weekly (research protocols vary widely). KPV 200-500 mcg oral or subq 2-3x daily during acute phases.
The above represents protocols reported in research literature and research community use. These are not recommendations for human dosing or self-administration.
Reported Research Outcomes
Research has examined this combination in chronic infection contexts, post-viral fatigue, and chronic inflammatory response syndromes. Outcomes are heterogeneous given the diversity of underlying conditions.
Cautions & Considerations
Patients with autoimmune disease should be cautious — even immune modulators can shift autoimmune balance. LL-37 has potential for histamine release and hypotension at higher doses. This stack is not appropriate for researchers with active malignancy or transplant immunosuppression.
Research Use Only — Compliance Notice
The peptides discussed in this stack are sold for research purposes only. None of this content is medical advice or intended to diagnose, treat, cure, or prevent any disease. Statements have not been evaluated by the FDA. Always consult a qualified medical professional before considering any peptide-related protocols.
